Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Trial Profile

A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms SPIRIT-H2H
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 17 Dec 2018 Results preseted in Eli Lilly and Company Media Release,
    • 17 Dec 2018 Status changed from active, no longer recruiting to completed, according to Eli Lilly and Company media release.
    • 17 Dec 2018 According to an Eli Lilly and Company media release, company plans to submit detailed data from this study for disclosure at scientific meetings and in peer-reviewed journals in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top